Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095823 · ClinicalTrials.gov registry record · Phase 3
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
NCT00095823 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,200 participants.
The verdict
NCT00095823, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
Study Summary
This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.
Interventions
- DRUG Antidepressant + Placebo
- DRUG Antidepressant + Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2004-06 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095823
The ClinicalTrials.gov registry entry for NCT00095823 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Antidepressant + Placebo is the first listed.
NCT00095823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095823 about?
NCT00095823 is a clinical study titled "A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder". This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.
What is the current status of trial NCT00095823?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2004-06. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00095823?
The interventions under investigation include: Antidepressant + Placebo (DRUG), Antidepressant + Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00095823?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.